LivingGLP1
Study S003278

An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [14C]-LY3549492 in Healthy Participants

ClinicalTrials.gov record

Registration

Registration
NCT06194500
Study type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Phase
PHASE1
Masking
NONE
Status
COMPLETED
Enrollment
18
Start
2024-01-03
Primary completion
2024-02-15
Lead sponsor
Eli Lilly and Company
Conditions
Healthy Male
Interventions
DRUG:[14C]-LY3549492; DRUG:LY3549492
Results posted
FALSE
Individual participant data sharing
NO
Secondary identifiers
OTHER:J3H-MC-GZNC; OTHER:U1111-1293-8652

Registered primary outcomes

  • Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A [Predose up to Day 24 postdose in Part A]
  • Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A [Predose up to Day 24 postdose in Part A]
  • Pharmacokinetic (PK): Area Under the Curve (AUC) for Oral Determination of Absolute Bioavailability (F) of LY3549492 in Part B [Predose up to Day 7 postdose in Part B]
  • PK: AUC for Intravenous (IV) Determination of Absolute Bioavailability (F) of LY3549492 in Part B [Predose up to Day 7 postdose in Part B]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.